Please login to the form below

Not currently logged in

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

BMS HQCombining Bristol-Myers Squibb's PD-1 inhibitor Opdivo and older melanoma drug Yervoy boosted progression-free survival (PFS) compared to Yervoy alone in a clinical trial.

The data - reported at the American Association of Cancer Research (AACR) meeting in Philadelphia - showed that the combination achieved an objective response rate (ORR) of 61% compared to 11% for Yervoy alone when given to previously-untreated patients with advanced (stage III or IV) melanoma

That looks encouraging given trials of Opdivo (nivolumab) as a monotherapy in this patient group revealed an ORR of around 40%, although different trial designs clearly mean no direct comparison can be made.

Giving Opdivo alongside anti–CTLA-4 antibody Yervoy (ipilimumab) resulted in a complete response in 22% of patients, while PFS was increased by 60% and - at the time of reporting - had still not reached a median after 11 months of follow-up.

Michael Giordano, head of oncology development at BMS, said the "results reinforce our belief that the future lies in the combination of immuno-oncology agents".

CTLA-4 and PD-1 exert their effects through complementary mechanisms and in preclinical models inhibiting both seems to have a synergistic improvement on anti-tumour activity.

The results have also been published in the New England Journal of Medicine (NEJM), with the authors concluding that the combination "resulted in durable responses and a substantially higher objective response rate, longer progression-free survival, and higher rates of complete response than ipilimumab monotherapy."

Yervoy quickly established itself as one of the cornerstones of melanoma therapy after launch and achieved sales of $1.3bn last year, and the new add to the body of evidence suggesting Opdivo should be used earlier in therapy than at present.

At the moment Opdivo - along with rival drug Keytruda (pembrolizumab) from Merck & Co - are approved as second-line agents for melanoma after treatment with Yervoy or a BRAF inhibitor such as Roche's Zelboraf (vemurafenib) and GlaxoSmithKline's Tafinlar (dabrafenib) if the patient's tumour is BRAF V600 mutation positive. 

Like Opdivo, Keytruda has also shown superiority to Yervoy in a head-to-head clinical comparison also reported in the NEJM this week.  

Moreover, both drugs were endorsed as first-line treatments by the National Comprehensive Cancer Network in the US - which means that insurers will likely reimburse them in this setting even ahead of formal approval of first-line use, and there is already evidence of off-label use in combination with Yervoy.

ISI Evercore analyst Mark Schoenenbaum said in a research note that the combination of Opdivo and Yervoy is likely to become the standard of care for first-line melanoma therapy. Further insights into the benefits of combining the two drugs will come with the results of the phase II CheckMate-067 study, which is due to complete in September 2016.

Article by
Phil Taylor

21st April 2015

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...